Vivo Capital, LLC Akero Therapeutics, Inc. Transaction History

Vivo Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$24.81 - $32.35 $16.7 Million - $21.8 Million	-673,280 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$24.04 - $34.19 $958,090 - $1.36 Million	39,854 Added 6.29%	673,280 $19.5 Million
Q4 2020 Feb 16, 2021	BUY	$25.12 - $29.89 $1.55 Million - $1.84 Million	61,593 Added 10.77%	633,426 $16.3 Million
Q3 2020 Nov 13, 2020	SELL	$30.79 - $39.92 $595,355 - $771,893	-19,336 Reduced 3.27%	571,833 $17.6 Million
Q2 2020 Aug 14, 2020	SELL	$19.25 - $26.76 $4.18 Million - $5.81 Million	-217,078 Reduced 26.86%	591,169 $14.7 Million
Q1 2020 May 15, 2020	BUY	$12.8 - $27.05 $10.3 Million - $21.9 Million	808,247 New	808,247 $17.1 Million

210

74.3M

321K

558K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.08B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Vivo Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Vivo Capital, LLC with notifications on news.